Immunotherapy and Targeted Therapies in NSCLC: Phase 3 Data From ESMO 2022
Results from the CodeBreak 200, EMPOWER-Lung 1, IPSOS, and ADAURA trials highlight the efficacy of immunotherapy and targeted therapies in non-small cell lung cancer.
Lung Cancer
LUNG CANCER ADVISOR
FEATURED CONTENT
-
-
Sublobar Resection Should Be New Standard Care for Certain Patients With NSCLC
Sublobar resection is noninferior to a full lobectomy in patients with carefully staged cT1aN0 non-small cell lung cancer, new research suggests. -
Research May Explain How Air Pollution Causes Lung Cancer in Never-Smokers
New research suggests that oncogenic mutations and air pollution work together to cause lung cancer in patients without a history of smoking. -
Does Smoking Marijuana Increase the Risk of Lung Cancer? The Jury’s Still Out
Studies have indicated that smoking marijuana may not increase a person’s risk of lung cancer, but robust evidence is lacking. -
Many Patients With Advanced NSCLC Do Not Survive Beyond First-Line Therapy
Many patients with advanced non-small cell lung cancer do not survive long enough to receive second-line therapy, a real-world study suggests.
LUNG CANCER NEWS
Molecular Testing May Be Underused, Delaying Therapy in Metastatic NSCLC
Adding Ipilimumab to Standard Care Improves Responses in Operable NSCLC
Pentagon Study Finds Higher Cancer Rates Among Pilots, Ground Crews
Hormone Therapy Linked to Lower Risk of Lung Cancer in Postmenopausal Women
Discrimination Tied to Frailty in African-American Cancer Survivors
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lung Cancer
Loading... 
Loading...